B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice

B cell hyperactivity and breach of tolerance constitute hallmarks of systemic lupus erythematosus (SLE). The heterogeneity of disease manifestations and relatively rare prevalence of SLE have posed difficulties in trial design and contributed to a slow pace for drug development. The anti-BAFF monocl...

Descripción completa

Detalles Bibliográficos
Autores principales: Parodis, Ioannis, Stockfelt, Marit, Sjöwall, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381321/
https://www.ncbi.nlm.nih.gov/pubmed/32754605
http://dx.doi.org/10.3389/fmed.2020.00316

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381321/
https://www.ncbi.nlm.nih.gov/pubmed/32754605
http://dx.doi.org/10.3389/fmed.2020.00316

Ejemplares similares